Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease

Nicolaus Kröger (2016), NEJM Link to abstract    

This is a prospective, multicenter, open-label, randomized phase III study with analysis of the use of ATG as part of the myeloablative conditioning regimen for adults with leukemia undergoing allogeneic peripheral-blood HLA-identical sibling stem cell transplant. After 2 years, the cumulative incidence of chronic GVHD was 32.2% in the ATG group and 68.7% in the non-ATG group. Survival rate was similar but the composite end point of chronic GvHD-free survival and relapse-free survival was higher with ATG.


* ATG was effective to prevent chronic GVHD in transplant when using peripheral blood stem cell source in matched sibling stem cell transplants without increasing OS.